Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: A dose-response-based meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3746-3755

  Mandema, Jaap W ^a   Zheng, Jenny ^b   Libanati, Cesar ^b   Ruixo, Juan Jose Perez ^b  

^a Quantitative Solutions   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; IBANDRONIC ACID; LASOFOXIFENE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; BONE DENSITY; DISEASE COURSE; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; EXPLORATORY RESEARCH; FEMALE; HIP DISEASE; HUMAN; LUMBAR SPINE; META ANALYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINE DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG EFFECTS; FRACTURES, BONE; LUMBAR VERTEBRA; MIDDLE AGED; NONLINEAR SYSTEM; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY; PREDICTIVE VALUE; REGRESSION ANALYSIS; TIME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; LEAST-SQUARES ANALYSIS; LUMBAR VERTEBRAE; MIDDLE AGED; NONLINEAR DYNAMICS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 84907646428     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3795     Document Type: Article

References (44)

1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
2. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
3. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24:182-195.
4. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-831.
5. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149-2157.
6. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
7. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153-161.
8. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with onceweekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141-151.
9. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin. 2003;19:383-394.
10. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin. 2008;24:207-213.
11. Recker RR, Kendler D, Recknor CP, et al. Comparative effects of raloxifene and alendronate on fracture out comes in postmenopausal women with low bone mass. Bone. 2007;40:843-851.
12. Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med. 2004;255:503-511.
13. Luckey M, Kagan R, Greenspan S, et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause. 2004;11:405-415.
14. Adami S, Passeri M, Ortolani S, et al. Effectsof oral alendronate and intranasal salmon calcitoninonbone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone. 1995;17:383-390.
15. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:4528-4535.
16. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008;26:753-767.
17. Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008;23:1155-1167.
18. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
19. Austin M, Yang YC, Vittinghoff E, et al; FREEDOM Trial. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27:687-693.
20. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677-692.
21. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004;44:951-965.
22. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589-624.
23. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther. 2002;24:1-20.
24. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192-208.
25. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain-results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia. 2005;25:715-725.
26. Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005;7:E513-E522.
27. Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: A randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin Exp. 2002;63:606-620.
28. Shiraki M, Kushida K, Fukunaga M, et al. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J. 1998;45:191-201.
29. Uchida S, Taniguchi T, Shimizu T, et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab. 2005;23:382-388.
30. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of a lend ronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J. 2008;49:119-128.
31. Shiraki M, Fukunaga M, Kushida K, et al. A double-blind doseranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int. 2003;14:225-234.
32. Kishimoto H, Fukunaga M, Kushida K, et al. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab. 2006;24:405-413.
33. Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab. 2008;26:624-634.
34. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month openlabel phases. Bone. 2010;47:493-502.
35. Itabashi A, Yoh K, Chines AA, et al. Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res. 2011;26:519-529.
36. Morii H, Ohashi Y, Taketani Y, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results fromarandomized placebo-controlled trial. Osteoporos Int. 2003;14:793-800.
37. Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98:4483-4492.
38. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811-818.
39. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
40. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010;86:202-210.
41. Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM. Goal-directed treatment of osteoporosis. J Bone Miner Res. 2013;28:433-438.
42. Pérez Ruixo JJ, Zheng J, Mandema JW. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy [published online November 11, 2013]. J Clin Pharmacol. doi:10.1002/jcph.228.
43. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetics meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793-807.
44. Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A doseresponse meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011;90(6):828-835.